Heparin-induced thrombocytopenia (HIT) is a rare but dangerous complication of heparin prophylaxis or treatment. The present laboratory tests to measure heparin-associated antibodies are not specific. The diagnosis of HIT mainly depends on the decrease in platelet count and on clinical symptoms. To evaluate clinical outcome, bleeding complications and platelet counts were evaluated in 45 patients with HIT type II (HIT II) treated prophylactically (subcutaneous injections) or therapeutically (intravenous infusion) with danaparoid. Group I included 24 patients with HIT II without thromboembolic complications who received danaparoid twice daily subcutaneously (10 IU/kg) for a mean of 16 days. Group II included 21 patients with thromboembolic complications. They were treated with The antibody-related heparin-induced thrombocytopenia (HIT type II [HIT II]) represents an important medical side effect. In its severe form, thromboembolic complications are frequent (1) (2) (3) (4) . HIT II occurs more frequently with unfractionated heparin (UFH) than with low-molecular-weight heparins (LMWH) (5).
esis of the pathophysiology of HIT II is based on the development of an IgG antibody to the heparin-PF4-complex, which also recognizes the FcyRIIA receptor on platelets (12, 13) . Binding of this complex causes platelet aggregation and thrombin generation. This concept is probably incomplete because the interactions between endothelium and antibodies are still not fully understood (14) . The antibodies are not heparinspecific and have been shown to react with LMWHs and dermatans (6, 15) . Endothelial cells are probably involved in the mechanism via binding of the antibody to glycosaminoglycans on the cell surface (9) but also to other endothelial epitopes (14) . Damaged endothelial cells may well be the starting point for thrombotic complications.
In many patients treated with UFH or LMWH (5%-30%), antibodies develop against heparin with differences according to the test system used. In only a minority of these patients with a positive antibody test (10%-15%), thrombocytopenia occurs and even fewer patients have thrombotic complications (10, (15) (16) (17) . This reduces the value of all presently available diagnostic assays for HIT II as reported by other authors (18) . Approximately 50% of patients highly suspected of having HIT II may experience thrombotic complications resulting in high rates of amputation and mortality (1, 19) . Patients with HIT II need early alternative anticoagulation to prevent these complications. The present tests for antibody detection in these patients are very unspecific and do not contribute much to the correct diagnosis. The diagnosis of HIT II depends on a high level of suspicion and experience. Physicians should therefore be aware that a decrease in platelets, the occurrence of venous/arterial thrombosis and/or rethrombosis, and skin necroses despite apparently adequate anticoagulation with UFH or LMWHs are highly suspicious findings for HIT II. If thrombocytopenia occurs, other clinical or drug-related causes for the decrease in platelets have to be excluded. The decrease of platelets begins most frequently on days 5 to 10 after heparin exposure, reaching ranges of 50,000/ALL to 70,000/ALL. In contrast to other drug-related disorders, HIT II is rarely associated with bleeding complications.
Hirudin and danaparoid sodium are approved for alternative anticoagulation in HIT II patients in Europe. Argatroban, another thrombin inhibitor, was effective in this indication in the United States (20) . Danaparoid is obtained from porcine intestinal mucosa and contains mainly heparan sulfate (84%) and dermatan sulfate (12%). The ratio of anti-Xa to anti-IIa activity is approximately 20:1. It has been used for many years for the prophylaxis as well as the treatment of patients with thrombotic disorders. A large experience has been reported from a compassionate use program (21) . Here we report on a prospective study in patients in whom HIT II was diagnosed clinically and who were successfully treated with danaparoid.
PATIENTS AND TREATMENT
We evaluated the clinical course and outcome of 45 patients with HIT. Pseudothrombocytopenia as well as other reasons for platelet decreases and other immunologically mediated diseases, medical/toxical side effects, blood loss/hemodilution, virus infections, marrow dysfunction, or disseminated intravascular coagulation have been excluded. Patients with potentially co-existing reasons for thrombocytopenia other than the exposure to heparin were not included in this trial. Laboratory assessments (heparin-induced platelet aggregation assay [HIPAA], PF4-ELISA) were not performed regularly but in at least 50% of all cases.
We found the following criteria helpful for diagnosing HIT II and for the exclusion of other causes of thrombocytopenia: a. Time of onset of the platelet decrease, which most probably occurs on Day 5 to 10 during anticoagulation with heparin. b. Continuous, more or less marked thrombocytopenia (at least 50% of baseline but rarely < 20,000/ALL).
c. Bleeding signs as petechiae or other hemorrhagic symptoms are less likely associated with HIT II. d. New venous or arterial 'thromboses after exclusion of inadequate anticoagulation as a potential underlying cause.
When there was a high suspicion of HIT II without clinical signs of thrombosis or thromboembolic complications, the platelet count was monitored every four to six hours. In the case of a continuous, and/or strong platelet decrease (>50% compared with initial values) with or without the occurrence of any new thrombotic symptoms (arterial, or venous thrombosis, skin lesions/gangrene, infarctions of any organ) the heparin administration was immediately discontinued. Danaparoid prophylaxis was immediately started.
The decision to initiate danaparoid therapy is based on clinical findings (group II patients with new arterial or venous thrombotic complications), respectively, on the exclusion of other reasons for thrombocytopenia (group I/II patients); thus the laboratory assessments did not influence the decision to initiate the treatment with danaparoid especially in those patients who were tested and found to be negative for antibodies.
Danaparoid was given subcutaneously for prophylaxis of thromboembolism in patients without thromboembolic complications and intravenously for treatment in patients with thrombotic complications (deep venous thrombosis [DVT], progression of thrombus formation during heparin administration not due to inadequate anticoagulation, arterial occlusions). A continuous and significant platelet decrease (> 50% reduction of platelet count related to initial values) occurred in all patients. All patients received phenprocoumon starting 7-10 days after the initiation of danaparoid treatment. Danaparoid was discontinued when an International Normalized Ratio (INR) of greater than 2 was reached.
Clinical and Laboratory Assessments
Medical history, physical examination, and existing laboratory data were evaluated before starting danaparoid. Clinically suspected thromboembolism had to be verified by objective methods (compression sonography, venography, angiography, ventilation/perfusion scans, computed tomography).
Initially platelets were counted daily. Phenprocoumon treatment was monitored using INR. For monitoring danaparoid, anti-factor-Xa activity levels were measured using an amidolytic assay (Coatest®, Chromogenix-M6lndal/Sweden).
For the detection of antibodies, the HIPAA (22,23) and the platelet factor 4/heparin complex enzyme-linked immunosorbent assay (ELISA) (Asserachrom Diagnostica Stago, Asnieres-sur-Seine) (24) were performed. Statistical analysis was performed using the Wilcoxon's rank test and the chi-square assay for the correlation of data.
RESULTS

Group I
Twenty-four patients (females to males, 12:12; mean age, 60.3 + 17.1 years) with HIT type II without thromboembolic complications belonged to this group. Anticoagulation with UFH (480-810 U/h, mean: 659 U/h ± 370 IU/h; 21 patients), or LMWH (Fragmin®, 3 patients) preceded a continuous platelet decrease. Eighteen patients were hospitalized for surgery; 6 patients suffered from internal non vascular diseases. A significant (>50%) platelet decrease compared with initial values and/or continuous decrease of platelets led to the initiation of an alternative anticoagulation on Day 11.5 ± 6.7. Before starting danaparoid prophylaxis (mean dose, 77.9 ± 47.7 U/h; 1.1 + 0.7 U/kg BW/h) the mean platelet count dropped to 83,100/,L ± 74,000/uL.
The patients received twice daily subcutaneous doses of 10 IU/kg body weight. In 3 patients with a known history of DVT, higher subcutaneous doses of danaparoid corresponding with intended anti-Xa levels of 0.2 to 0.3 U/mL were applied. The dosage and corresponding anti-Xa levels ranging from 0.14 U/mL to 0.36 U/mL (mean: 0.22 ± 0.15 U/mL) are demon-strated in Tables 2 and 3. In Fig. 2 the course of platelet count during anticoagulation with danaparoid is shown. The platelet count normalized within 5 to 7 days after the initiation of danaparoid administration, which was well tolerated in all cases. Hospitalization lasted for 35 There was only a weak correlation between the dosage of danaparoid and the anticoagulant effects (Fig. 1 ). This became more evident in the group of patients with thromboembolic complications (r = 0.31) than in the group that received danaparoid prophylactically (r = 0.7).
The platelet count increased to normal levels within 3 days (Fig. 2, Table 3 ). Recurrent thrombocytopenia did not occur. Hospitalization lasted for 38.7 ± 25.2 days. No amputation became necessary because no recurrence of thrombosis/extension of thrombus formation or letal outcome occurred. Bleeding complications were also not observed. Laboratory assessments for HIT II were performed in 37/45 cases (HIPAA-group I, 20/24 patients; group II, 17/21 patients). The PF4 ELISA testing was performed in 19 of 45 patients (group I, 10/24 patients; group II, 9/21 patients). Despite the clinical evidence of HIT II, negative results were observed in both groups (group I/II-patients) more often than positive findings. Furthermore positive HIPAA and positive ELISA results were found in only 3 patients (group I), and 5 patients (group II), respectively, while there were discrepant results in 13 patients (group I) and 10 patients (group II) ( Table 3 ). In 4 patients of both groups, the HIPAA was not performed or data were unavailable and/or not representative because of a delay in transport or a potential washout phenomenon due to an early initialization of alternative anticoagulation. In vitro crossreactivity to danaparoid was verified in none of the 19 patients tested by the PF4 ELISA. In two patients a positive testing could not be confirmed because 2 of 4 test cells had positive results, and/or an increase of platelet activation was retrospectively found to be possibly independent from heparin.
DISCUSSION
Heparin-induced thrombocytopenia is an important medical side effect potentially associated with high lethality and amputation rates. Heparin, PF4, and/or other platelet proteins create immuncomplexes that mediate platelet aggregation, secretion of platelet products, and microparticles resulting in a vicious circle of progressive thrombus formation. A minimum of 12 saccharide units may be necessary for heparin to interact with its coantigen, PF 4. Thus less antigen formation may occur in vivo in patients treated with LMWHs (25) . LMWHs cannot be recommended for anticoagulation in HIT II patients because recurrent/progressive thrombocytopenia has been observed (19) . Danaparoid has been described to crossreact in vitro with UFH-induced antibodies in 10% to 40% (26) , which may be attributed to heparan sulfate. Otherwise the antibody is found not to be highly specific (6) . Animal models have shown a high benefit/risk ratio (antithrombotic effects versus bleeding) with danaparoid (27, 28) . This was confirmed in surgical and stroke patients in the prevention of DVT (4, (29) (30) (31) (32) (33) and in the treatment of patients with DVT (34) .
Hyperreactivity of platelets may not only be due to the immunologically mediated platelet stimulation but also be induced by different clinical/pathophysiologic circumstances in multimorbid patients such as trauma, cancer, inflammatory or infectious disease, septicemia, endothelial damage, shear stress, and drug interferences resulting in false-positive results of functional assays (platelet aggregation assay [PAA], or 14C serotonin release assay). It has been demonstrated in several prospective clinical trials that positive results on antibody assays are found much more frequently than HIT 11 (16, 17, 35) . Apparently no laboratory parameter at present allows the diagnosis of HIT II. Antibodies develop without HIT. Laboratory assessments for heparin antibodies (PF 4 ELISA) as well as the HIPA assay therefore are of limited value to confirm the diagnosis of HIT II.
The validity of crossreactivity testing is questionable because translation into clinical reactions is rather hypothetical.
Our clinical experience with danaparoid throws doubt on the clinical significance of in vitro crossreactivity testing. Patients at high risk for HIT II cannot be identified by laboratory analysis; watchful waiting and short-term platelet control within may be adequate. Early alternative anticoagulation is necessary especially in patients in whom thrombocytopenia is associated with thromboembolic complications (36) .
Data on the efficacy of danaparoid in patients with HIT II are limited to those obtained from a large noncomparative worldwide compassionate use program (21, 37, 38) , a prospective trial comparing the drug with dextran (39), and small series of patients with HIT II-associated thromboembolic complications (40, 41) .
Despite positive in vitro crossreactivity registered in 10% to 40% of patients treated with danaparoid, clinical signs of HIT II are extremely rare. If there is a lack of improvement of clinical signs, with deterioration in platelet counts in patients receiving danaparoid, the anticoagulant therapy should be changed. Therefore a continuous registration of platelet counts during the alternative anticoagulation is mandatory.
Our data demonstrate that danaparoid can be considered as a first-choice alternative anticoagulant in patients with HIT II. It can be used safely and effectively. Anti-Xa levels of 0.4 U/mL seem to be sufficient to prevent recurrence or extension of thrombosis and bleeding complications. The anti-Xa levels seemed to be better correlated with the prophylactic doses than the intravenous (lV) therapeutic regimen. This also underlines the difficulty to correlate antithrombotic and anticoagulant efficacy by anti-Xa measurements.
In the patient group that received the higher danaparoid doses, the platelet counts rose higher and normalized faster than in patients who received lower subcutaneous danaparoid doses. These data suggest to treat all HIT II patients with the higher danaparoid regimen, even if they present no thromboembolic complications because no bleeding complications occurred at all.
Clinicians should not hesitate to start alternative anticoagulation. But in patients highly suspected for HIT II, re-exposure to UFH should be avoided and its use should be documented in an emergency card.
Danaparoid has been shown to be effective and safe. Bleeding complications as recurrence of thrombosis or thrombus progression can be avoided with the use of doses corresponding with anti-Xa levels ranging at approximately 0.4 U/mL. The lower prophylactic subcutaneous regimen prevented thrombotic complications in our series.
